Nyrada Inc. Overview
Nyrada is a single-asset, clinical-stage Australian biotechnology company, incorporated in Delaware. Its platform is the inhibition of Transient Receptor Potential Canonical (TRPC) 3/6/7 ion channels. Its lead molecule, Xolatryp®, is a first-in-class intravenous small molecule designed to limit pathological calcium influx into cells exposed to ischaemic or toxic stress. Xolatryp completed a 48-subject Phase I trial in healthy volunteers in 2025 with no serious adverse events. In July 2026 it entered PROTECT-MI, a 100-patient, randomised, placebo-controlled Phase IIa trial in STEMI heart-attack patients undergoing primary PCI. No approved therapy exists for myocardial ischaemia-reperfusion injury. Preclinical data also support use in ischaemic stroke, traumatic brain injury and anthracycline (doxorubicin) cardiotoxicity, plus possible anti-tumour additivity. Nyrada has no product revenue and funds itself through equity and Australia's refundable R&D tax incentive. A A$12m placement in September 2026 is intended to fund PROTECT-MI to topline data, expected in 2H CY2027.
Company's own description
Nyrada describes itself as a clinical-stage biotechnology company focused on discovering and developing innovative small-molecule therapies that target TRPC ion channels. It states that its lead candidate, Xolatryp®, has shown efficacy in preclinical cardioprotection, neuroprotection and oncology models, has completed a first-in-human Phase I trial, and is now in a Phase IIa trial assessing safety and preliminary efficacy in reducing cardiac reperfusion injury in STEMI patients undergoing PCI (FY2026 Full Year Results, 18 Aug 2026).
The FY2023 Annual Report gave the strategic framing that still applies. The vision was to become a high-growth pharmaceutical discovery and development company specialising in early-stage development of novel treatments. The strategy was to target diseases with unmet clinical need or suboptimal current treatments, and to monetise them by advancing highly optimised drug candidates.
Independent characterisation
Nyrada is a pre-revenue, single-mechanism, single-lead-asset drug developer. Its business model is "develop-to-partner." At IPO in 2020, CEO James Bonnar described the plan as taking drug candidates up to about Phase IIa and then selling or licensing them (Small Caps, Feb 2020). The FY2026 materials and the September 2026 raise are consistent with that plan: they prioritise a clean Phase IIa readout, a US FDA IND, a commercial dose form, and a follow-on oral TRPC inhibitor. These are the assets a pharmaceutical licensee would want to see.
Revenue model
| Revenue type | Status | Comment |
|---|---|---|
| Product sales | — | No approved products |
| Services | — | — |
| Subscription | — | — |
| Licensing / milestones | None to date | Intended future model: out-license or sale after Phase IIa |
| "Other income" | Recurring | Mainly the Australian refundable R&D tax incentive, plus interest income. Reported "revenue" of A$2.56m in FY2025 was of this nature. |
Value-chain position
Nyrada covers discovery and preclinical pharmacology through early clinical development (Phase I–IIa). Medicinal chemistry, GLP toxicology, drug manufacturing (CMC), clinical operations and preclinical efficacy studies are outsourced to contract research and manufacturing organisations and academic collaborators. The specific CROs and CDMOs are not publicly named in the sources reviewed. Commercial manufacturing, late-stage trials and commercialisation would fall to a future partner.
Customer types and end-markets
There are no current customers. The prospective customers are large and mid-cap pharmaceutical companies with interests in acute cardiology, cardio-oncology, critical care or neurology. Ultimately, the drug would be prescribed in hospitals:
-
Interventional cardiology: STEMI patients undergoing primary PCI
-
Cardio-oncology: patients receiving anthracycline chemotherapy such as doxorubicin
-
Acute neurology: ischaemic stroke and traumatic brain injury
-
Possible extension to oncology combination therapy (preclinical anti-tumour additivity with doxorubicin)
Strategy
Stated strategy (themes from FY2026 results and the Sept 2026 raise)
-
FY2026 was described as "transformational": the company completed first-in-human work and moved into patient testing.
-
FY2027 priorities: (1) advance PROTECT-MI to conclusion and data readout; (2) lodge an IND with the US FDA; (3) move other preclinical programs toward the clinic to enhance Xolatryp's value.
-
Sept 2026 capital-raise priorities, per the CEO: complete Phase IIa, broaden the pipeline, develop an oral TRPC asset, and develop a commercial dose form of Xolatryp.
Initiatives announced in the last 24 months
| Initiative | Timing | Detail | Status |
|---|---|---|---|
| Phase I first-in-human trial | Feb–Aug 2025 | 48 healthy volunteers, staged cohorts | Completed; positive |
| PROTECT-MI Phase IIa | HREC Jan 2026; first patient Jul 2026 | Randomised, double-blind, placebo-controlled; 100 evaluable patients, 1:1; primary endpoint safety and tolerability; secondary endpoints infarct extent, cardiac function, troponin I and arrhythmias | Recruiting; topline Q3/Q4 CY2027 |
| US FDA IND | Pre-IND meeting requested after year-end | IND for the myocardial ischaemia-reperfusion injury program | Submission targeted before end of CY2026 |
| Oncology expansion | May–Aug 2026 | Anti-tumour and cardioprotection studies with doxorubicin | Phase Ib feasibility under assessment |
| Stroke program | FY2027 | Prerequisite stroke model to support a Phase IIa | Funded |
| Oral TRPC inhibitor | FY2027 | Next-generation, orally dosed molecule | Initiation funded |
| Commercial dose form | FY2027 | CMC development | Funded |
| IP fortification | FY2026 | Composition-of-matter patent allowed; trademark granted | Achieved |
ESG commitments and cost programs
No formal ESG targets or cost-reduction programs with numerical targets are disclosed. Management cites disciplined capital and cost management.
Medium-term targets and guidance
No financial guidance is given, which is standard for a pre-revenue biotech. Operational guidance:
-
Safety review after the first 8 PROTECT-MI patients: 2H CY2026
-
Last patient dosed: mid-CY2027
-
Topline results: about three months after last-patient follow-up, so Q3/Q4 CY2027
-
IND submission: before end of CY2026
-
FY2026 R&D rebate (A$1.72m): quarter ending 31 Dec 2026
Products & Services
All assets sit in the single discovery and development segment. None is marketed and no pricing exists.
Xolatryp® (formerly NYR-BI03), the lead asset
| Attribute | Detail |
|---|---|
| Modality | Small molecule; intravenous infusion in PROTECT-MI. Subcutaneous dosing tested preclinically for oncology. |
| Mechanism | Inhibits TRPC3, TRPC6 and TRPC7 channels to limit excessive Ca²⁺ entry into stressed cells. Mechanistic work with WRAIR/UNSW indicates mitochondrial stabilisation and reduced mitochondrial calcium loading in brain cells. |
| Clinical status | Phase I complete (48 healthy volunteers; all doses safe and well tolerated; no dose-limiting toxicities or serious adverse events; therapeutic exposure within 10 minutes; linear, predictable pharmacokinetics with no sex differences). Phase IIa (PROTECT-MI) recruiting since July 2026. |
| IP | US composition-of-matter patent allowed (Notice of Allowance, May 2026). Once the issue fee is paid, it protects the chemical structure for 20 years from the September 2024 priority date (to about September 2044, before any extension). Composition-of-matter application published. Xolatryp® trademark granted. |
| Target customer | Hospital interventional cardiology, cardio-oncology and acute neurology. Commercial counterparty: a pharma licensee. |
| Launch year | Not applicable (investigational) |
| Program | Indication | Stage | Key data | Next step |
|---|---|---|---|---|
| Myocardial ischaemia-reperfusion injury | STEMI patients undergoing primary PCI | Phase IIa (PROTECT-MI) | Phase I safety; preclinical cardioprotection studies 1a, 1b and 2 | Safety review after first 8 patients (2H 2026); topline Q3/Q4 CY2027; US IND before end of CY2026 |
| Myocardial ischaemia & arrhythmia control | Arrhythmia incidence after MI | Exploratory endpoint inside PROTECT-MI | Listed as a company program on the website | Read-out with PROTECT-MI |
| Anthracycline cardiotoxicity (cardio-oncology) | Doxorubicin-induced cardiomyopathy | Preclinical, completed | 5-week rodent study: significant protection across four cardiac-function measures, comparable to dexrazoxane (see 5.2) | Phase Ib oncology/cardioprotection trial being assessed and partly funded by the Sept 2026 raise |
| Oncology combination | Liver cancer model with doxorubicin | Preclinical | Tumour-volume change at Day 14: Xolatryp alone -32%, doxorubicin alone -41%, combination -57% | Feeds into Phase Ib design |
| Ischaemic stroke | Acute neuroprotection | Preclinical | Statistically significant neuroprotection (stroke study, Feb 2024) | A prerequisite stroke model, funded by the Sept 2026 raise, to support a Phase IIa stroke study |
| Traumatic brain injury | Secondary brain injury after TBI | Preclinical | Significant neuroprotection (Apr 2025); reduced mitochondrial Ca²⁺ loading (WRAIR/UNSW) | No funded clinical step disclosed |
Indication-by-indication catalog
Cardiomyopathy study detail (21 August 2026 release)
| Arm | Change vs baseline (%) |
|---|---|
| Doxorubicin alone | -46.0 |
| Doxorubicin + Xolatryp | -30.3 |
| Doxorubicin + dexrazoxane (the approved cardioprotectant) | -32.6 |
One cardiac-function parameter was reported by secondary coverage as follows. The specific parameter, likely an ejection or shortening measure, is not named in the secondary source.
Xolatryp versus doxorubicin gave p<0.0001 on that measure. Structural and histopathological findings supported the functional results. The company explicitly said the study was not designed or powered to show superiority to dexrazoxane, and that preclinical results may not translate to humans.
Pipeline extensions (pre-candidate)
| Asset | Description | Status |
|---|---|---|
| Next-generation oral TRPC inhibitor | Orally dosed TRPC inhibitor for chronic or outpatient indications | Initiation funded by the Sept 2026 raise |
| Xolatryp commercial dose form | CMC work toward a commercial formulation | Funded by the Sept 2026 raise |
Legacy or deprioritised programs (disclosed at IPO and in 2021)
| Program | Description | Current status |
|---|---|---|
| Oral PCSK9 inhibitor (from the Cardio Therapeutics acquisition) | Oral small molecule to lower LDL-cholesterol in patients who respond poorly to or cannot take statins | Not in current pipeline disclosures. |
| NYX-1010 (brain injury, IV/intranasal) | Earlier brain-injury compound named in 2021 coverage | Superseded by NYR-BI03/Xolatryp |
| Peripheral nerve pain; autoimmune (e.g. psoriasis) | Early discovery programs listed by data aggregators | Not in current disclosures |
Financial Narrative
Important framing: Nyrada is pre-revenue. Revenue, gross profit and EBITDA-based margins, revenue CAGR, ROIC, interest coverage, asset turnover and the cash conversion cycle are therefore not meaningful. They are listed below and left blank. "Income" means other income, chiefly the R&D tax incentive and interest.
Income statement
Sources: Stockopedia income statement (FY2022–FY2025, from annual reports under Australian Accounting Standards); FY2025 Preliminary Final Report (income A$2,558,803; loss A$4,845,671); FY2026 Full Year Results (loss A$6.56m). FY2021 for reference: income A$2.34m, opex A$5.87m, net loss A$3.54m (Stockopedia).
Margins: Gross, operating, EBITDA and net margins are not meaningful with no product revenue. Revenue CAGR is not meaningful.
Half-year reference points: In H1 FY2025 (6 months to 31 Dec 2024) the loss was A$2.457m, versus a profit of about A$0.14m in H1 FY2024. H1 FY2025 R&D expenditure was A$1.81m and corporate/administration A$0.48m (Half Year Report to 31 Dec 2024).
Balance sheet
Sources: FY2024 cash A$4,769,374 (Half Year Report Dec 2024); FY2025 cash A$2.93m and FY2026 cash A$8.38m (FY2026 Full Year Results; the June 2026 Appendix 4C reports A$8.39m, a A$0.01m rounding discrepancy). Simply Wall St (Oct 2026) reports short-term assets of about A$10.4m exceeding liabilities, and no debt. Zero debt for FY2024–FY2025 is inferred from the absence of borrowings in disclosures and the 2021 repayment of the Noxopharm loan.
Interim cash track (AUD M)
Sources: Quarterly Activities Reports and Appendix 4C; Half Year Report Dec 2024.
Cash flow
FY2026 = August 2025 placement of A$8.25m, plus unquantified proceeds from option exercises.
Quarterly operating cash burn: about A$1.84m (Sep-2024 quarter), A$1.05m (Jun-2024 quarter), A$1.75m (Dec-2025 quarter) and A$0.51m (Mar-2026 quarter, reported net of R&D rebate timing effects). A full June 2026 quarter figure was not captured.
R&D tax incentive receipts and accruals (AUD M)
Sources: 1Q FY2025 4C (FY2024 claim re-estimated at A$1.38m; A$1.24m received in H1 FY2025 per Half Year Report); R&D rebate release of 29 May 2026 (A$2,454,848 received for FY2025; earlier estimate A$2.16m); FY2026 results (A$1.72m accrued). The FY2026 release says this will be received in the quarter ending 31 December 2026 in one place and "2025" in another. The latter is an evident typographical error.
Ratios
ROIC, net debt/EBITDA, interest coverage, asset turnover and the cash conversion cycle are not meaningful for a debt-free, pre-revenue developer. ROE and ROA are deeply negative in every year because there are recurring losses and no revenue.
Commentary on trends, inflections and drivers
FY2022–FY2023, a discovery-stage peak: With two parallel programs (PCSK9 and brain injury) running after the A$11m March 2021 raise, operating expenses peaked at A$9.36m in FY2023 and the loss at A$7.78m. The FY2023 Annual Report described a difficult capital-markets year.
FY2024, a trough in spend: Opex fell to A$4.79m and the loss narrowed to A$1.39m. Spending was reprioritised to a single TRPC asset, and income of A$3.40m (R&D incentive plus other items) was relatively high. The A$0.075 placement in March 2024 marks the low point in the company's cost of capital.
FY2025, the clinical transition: GLP toxicology, manufacturing and the start of Phase I pushed opex to A$7.40m and the loss to A$4.85m. Cash ended the year at only A$2.93m, about one to two quarters of runway, before the A$8.25m August 2025 placement. That placement was the key financing inflection.
FY2026, Phase IIa preparation: The loss widened to A$6.56m as the company finished Phase I, prepared Phase IIa (HREC approval, site start-up, drug supply) and ran oncology studies. Cash still rose to A$8.38m. The A$8.25m placement, the A$2.45m R&D rebate and option-exercise proceeds outweighed the spend.
FY2027 setup: The September 2026 placement (A$12.0m) plus cash and the expected R&D rebate takes stated available funding to about A$22.1m before the SPP, with A$15.8m earmarked for clinical development. Up to A$5.125m of this depends on holder approval of director participation, expected around February 2027. With a quarterly burn likely to rise as PROTECT-MI recruits, management states that the raise funds the trial through topline data.
Indicative analyst derivation (not a disclosed figure): Australia's refundable R&D tax offset for entities with turnover under A$20m is generally 43.5% of eligible spend. On that basis, the rebates imply eligible R&D spend of roughly A$3.2m (FY2024), A$5.6m (FY2025) and A$4.0m (FY2026). The FY2026 figure is lower because some overseas or ineligible costs may be excluded, and because Phase IIa patient costs mostly fall in FY2027. Treat these as indications only.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Products / programs |
|---|---|---|
Drug discovery & development (sole segment) | TRPC ion-channel inhibitor platform | Xolatryp® (IV), next-generation oral TRPC inhibitor (discovery), commercial dose-form development |
Results by Segment and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment income (AUD Mn, other income incl. R&D incentive) | 3.40 | 2.56 | — |
Segment result: loss after tax (AUD Mn) | -1.39 | -4.85 | -6.56 |
Share of group income (%) | 100 | 100 | 100 |
Income Statement
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total income incl. R&D incentive (AUD Mn) | 1.11 | 1.58 | 3.40 | 2.56 | — |
Total operating expenses (AUD Mn) | 5.07 | 9.36 | 4.79 | 7.40 | — |
Operating profit / loss (AUD Mn) | -3.96 | -7.78 | -1.39 | -4.85 | — |
Pre-tax profit / loss (AUD Mn) | -3.96 | -7.78 | -1.39 | -4.85 | — |
Net profit / loss after tax (AUD Mn) | -3.96 | -7.78 | -1.39 | -4.85 | -6.56 |
Dividends per share (AUD) | 0 | 0 | 0 | 0 | 0 |
Key Financials
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash and equivalents (AUD Mn) | 4.77 | 2.93 | 8.38 |
Total debt (AUD Mn) | 0 | 0 | 0 |
Net debt (AUD Mn) | -4.77 | -2.93 | -8.38 |
Key Financials (Sep-2024–Jun-2026)
| Metric | Sep-2024 | Dec-2024 | Sep-2025 | Dec-2025 | Mar-2026 | Jun-2026 |
|---|---|---|---|---|---|---|
Cash balance (AUD Mn) | 2.98 | 5.71 | 7.92 | 7.12 | 6.74 | 8.39 |
Balance Sheet
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Equity raised, gross (AUD Mn) | — | — | — | 3.36 | 8.25 |
Dividends paid (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Buybacks (AUD Mn) | 0 | 0 | 0 | 0 | 0 |
Key Financials (FY2024 claim–FY2026 claim)
| Metric | FY2024 claim | FY2025 claim | FY2026 claim |
|---|---|---|---|
Rebate (received, or accrued for FY2026) (AUD Mn) | 1.38 | 2.45 | 1.72 |
Financial Analysis
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Debt to equity (x) | 0 | 0 | 0 | 0 | 0 |
Results by Region
| Region | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Australia: total income (AUD Mn) | 3.40 | 2.56 | — |
Americas: income (AUD Mn) | 0 | 0 | 0 |
EMEA: income (AUD Mn) | 0 | 0 | 0 |
Other APAC: income (AUD Mn) | 0 | 0 | 0 |
Share Price History
| Date | Price | Context | Source |
|---|---|---|---|
16 Jan 2020 | 0.20 | IPO price | Stockhead |
Mar 2021 | 0.26 | Placement price | Biotech Dispatch |
Mar 2024 | 0.075 | Placement price (approximate cycle low) | Placement release |
Aug 2025 | 0.30 | Placement price | FY2026 results |
8 Jan 2026 | ~1.40 | At HREC approval; near 52-week high (~1.435) | InvestSMART |
19–20 Mar 2026 | ~0.51–0.54 | At PROTECT-MI commencement announcement | InvestSMART |
Jun 2026 | ~0.42–0.45 | Near the post-peak trough | InvestSMART |
6 Aug 2026 | 0.68 | — | InvestSMART |
Aug/Sep 2026 | 0.75 | Stockopedia close; implied market cap A$181.2m | Stockopedia |
~21 Sep 2026 | 0.62 | Placement price; 15.1% discount to last traded (implying about A$0.73) | Small Caps |
Valuation Snapshot
| Metric | Value | Source / note |
|---|---|---|
1-year return | About +176% | Stockopedia (snapshot Aug/Sep 2026); outperformed the All Ordinaries by about 176 percentage points |
3-year return | Price was A$0.075 in Mar 2024 against roughly A$0.5–0.75 in late 2026, implying a multi-bagger, but no exact 3-year base date is available. | — |
5-year return | The Mar 2021 placement was at A$0.26. | — |
Since IPO (A$0.20) | Positive; StoxRay showed +131% at A$0.52 (May 2026) | StoxRay |
Valuation Snapshot by Multiple
| Multiple | Value |
|---|---|
P/E | Not meaningful (loss-making) |
EV/Sales | Not meaningful (no revenue) |
Market cap | A$130.0m (Simply Wall St, Oct 2026) vs A$181.2m (Stockopedia, Aug/Sep 2026). The gap reflects price moves and possibly differing share counts after the September 2026 issue. |
Enterprise value (indicative) | Market cap less about A$20m of cash and receivables after the September placement (subject to settlement), giving an EV of roughly A$110–160m |
Capital Markets
| Item | Status |
|---|---|
Dividend history and policy | No dividends ever paid; none expected |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | No debt |
Analyst Conclusions
Management guidance (operational)
| Item | Timing |
|---|---|
| PROTECT-MI safety review (first 8 patients) | 2H CY2026 |
| US FDA IND submission | Before end of CY2026 (pre-IND meeting requested) |
| FY2026 R&D rebate (A$1.72m) | Quarter ending 31 Dec 2026 |
| Director placement approval general meeting | ~Feb 2027 |
| PROTECT-MI last patient dosed | Mid-CY2027 |
| PROTECT-MI primary completion (ClinicalTrials.gov) | 30 Jun 2027 (estimated) |
| PROTECT-MI topline data | Q3/Q4 CY2027 |
| Study completion (ClinicalTrials.gov) | 30 Sep 2027 (estimated) |
Consensus growth expectations: Not meaningful or not available for a pre-revenue company. Stockopedia shows FY2026E and FY2027E columns, but the values were not captured.
Bull case
-
A de-risked molecule entering a no-competitor niche. Clean Phase I safety, under-10-minute exposure and a 100-patient randomised Phase IIa give Nyrada the first credible TRPC readout in STEMI, an indication with no approved therapy. A positive efficacy signal on infarct extent or troponin I would be highly differentiated.
-
Dual-value cardio-oncology optionality. Preclinical data show cardioprotection comparable to the only approved agent (dexrazoxane) and anti-tumour additivity (-57% tumour volume for the combination vs -41% for doxorubicin alone). That supports a second, potentially faster Phase Ib-to-partnering pathway.
-
Funded, aligned and IP-protected. About A$22m of funding sources, US composition-of-matter protection to about 2044, and a transaction-savvy board that is putting in A$5.1m of its own money set up a licensing event after 2H CY2027 data without an interim forced raise.
Bear case
-
History is against cardioprotection. Cyclosporine, elamipretide and conditioning all failed in STEMI despite strong preclinical data. PROTECT-MI's primary endpoint is safety, so even a "successful" trial may give an efficacy signal too weak to secure a partner.
-
Execution and timeline risk. First dosing came about three months later than guided, only three of at least nine planned sites were active by September 2026, and STEMI recruitment depends on emergency workflows. Further slippage would push topline into 2028 and raise cash burn.
-
Valuation and dilution. A market cap of about A$130–180m for a single preclinical-to-Phase IIa asset with no revenue prices in substantial success. Attaching and piggyback options (A$0.93 and A$1.40) and serial raises imply continued dilution. The share price has already fallen from about A$1.40 (January 2026) to the A$0.40s within the past year, showing how sensitive the stock is to sentiment.
Key catalysts and monitorables (next 12 months)
| Catalyst | Expected timing | Why it matters |
|---|---|---|
| Sep-2026 quarter 4C | Late Oct 2026 | Cash after placement; burn rate; recruitment numbers |
| SPP result | Q4 CY2026 | Retail demand; up to A$2.0m |
| Safety Review Committee (first 8 patients) | 2H CY2026 | First patient-level safety signal |
| Pre-IND meeting and IND submission | By Dec 2026 | US regulatory validation; opens US sites |
| FY2026 R&D rebate receipt | Q4 CY2026 | A$1.72m of non-dilutive cash |
| Site activations (AU/NZ) | Rolling | Leading indicator for the mid-2027 last-patient target |
| General meeting on director participation | ~Feb 2027 | A$5.125m of funding contingency |
| Phase Ib oncology design decision | 1H CY2027 | Second clinical indication |
| Stroke prerequisite model data | CY2027 | Neurology pathway |
| Interim report | 17 Feb 2027 | H1 FY2027 financials |
Analyst verdict
Nyrada is now a different company from the two-program discovery shell that listed in January 2020. Over the past 18 months it has executed the hardest transition for a micro-cap biotech, from preclinical to patient-stage. It completed a clean 48-subject Phase I, won ethics approval, activated sites, and dosed the first STEMI patient in a randomised, placebo-controlled Phase IIa. It did this while securing US composition-of-matter protection to the mid-2040s and adding a second scientific story in cardio-oncology. In that model, preclinical cardioprotection matched dexrazoxane and tumour responses improved. The September 2026 raise of A$12.0m at A$0.62, more than double the August 2025 price, removes near-term funding risk through topline. The board's A$5.125m commitment is unusually strong alignment for a company of this size.
The investment case is still binary and back-end loaded. Value creation depends almost entirely on PROTECT-MI efficacy signals due in 2H CY2027, in an indication that has humbled many better-funded programs. Because the trial is safety-primary, investors and potential licensees will look closely at secondary measures such as infarct extent, troponin I and cardiac function. A 100-patient study may not power those convincingly. Execution risk is already visible: first dosing slipped three months, and the site network is still being built.
On balance, Nyrada is a well-governed, adequately funded, high-risk, high-optionality single-asset developer. The near-term risk-reward depends on milestones: the first-8-patient safety review, IND submission and recruitment cadence over the next two quarters will determine whether the CY2027 readout timetable is credible. For institutional investors, the position is best sized as a venture-style option on a first-in-class TRPC platform. Recruitment metrics in each Appendix 4C are the most important leading indicator to monitor.
Prepared from publicly available information as at 12 October 2026.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education |
|---|---|---|---|---|
James Bonnar | Managing Director & CEO | Joined Feb 2018; Board MD since 8 Oct 2025 | 11 years at Neuren Pharmaceuticals as Director, CMC & Regulatory Affairs, then Director, Clinical Operations, overseeing development in TBI and neurodevelopmental disorders. Earlier roles in diabetes research, GMP manufacturing and formulation. Over 20 years in life sciences. | BSc (Chemistry); MRQA |
Dr Benny Evison | Chief Scientific Officer | Among Nyrada's first scientists | Postdoctoral fellow at St Jude Children's Research Hospital, Memphis (DNA-repair targeting to enhance chemotherapy). PhD work on the mechanism of pixantrone. | BSc (Med Sci) (Hons), PhD, La Trobe University |
David Franks | Company Secretary | — | Automic Group | — |
Board of Directors
| Name | Role | Independence (analyst view) | Background |
|---|---|---|---|
John Moore | Non-Executive Chair | Independent non-executive | CEO of Acorn Energy (2006–2015): acquired CoaLogix for US$11m and later sold it for US$101m; took Comverge public. Partner and CEO of Edson Moore Healthcare Ventures (2002), which acquired 16 drug-delivery investments from Elan for US$148m. Chair of Scientific Industries (OTCQB: SCND) and Trialogics; director of Phase Holographic Imaging and Cormetech. Rutgers University. |
James Bonnar | Managing Director & CEO | Executive | See above |
Christopher Cox | Non-Executive Director | Non-executive | Co-founder and General Partner of Population Health Partners (since Apr 2020). Former EVP & Chief Corporate Development Officer of The Medicines Company (2016–2019). Former partner and Chair of the Corporate Department at Cadwalader, Wickersham & Taft. Boards: Scientific Industries, Niroda Therapeutics, Civia Health. |
Marcus Frampton | Non-Executive Director | Non-executive | Chief Investment Officer of the Alaska Permanent Fund Corporation (about US$85bn sovereign wealth fund). Previously at Lehman Brothers, PCG Capital Partners and LPL Financial. |
Dr Rüdiger Weseloh | Non-Executive Director | Independent non-executive | Executive Director, Business Development at EMD Serono (Merck KGaA), with over 80 transactions across 19 years. Former biotech equity analyst. Max Planck postdoctoral researcher. |
Dr Ian Dixon | Non-Executive Director | Non-executive; founder-vendor of Cardio Therapeutics | Co-founder of Cynata (ASX: CYP), Cardio Therapeutics and Exopharm (ASX: EX1). PhD in biomedical engineering (Monash), MBA (Swinburne). |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
8 Oct 2025 | James Bonnar appointed Managing Director | Executive representation on the Board ahead of Phase IIa |
Nov 2025 | Gisela Mautner retired | Followed Noxopharm's full exit from the register in May 2025 |
Major Shareholders
| Holder | Stake | Comment |
|---|---|---|
Board and management (aggregate) | Not precisely disclosed; material | Bought about 26% of Noxopharm's exited parcel (May 2025). Board committed A$5.125m to the Sept 2026 placement (subject to approval). |
Noxopharm Limited | 0% | Held 30.51% at IPO, then 18.60%, then 5.13%, then fully exited in 2025 |
Substantial holders | Not captured | — |
Competitive Landscape
Competitors by Segment
| Indication | Competitor / product | Owner | Mechanism | Stage / status (as last known) |
|---|---|---|---|---|
STEMI reperfusion injury | FDY-5301 (IV sodium iodide) | Faraday Pharmaceuticals (private, US) | Reductive antioxidant | Late-stage (IOCYTE AMI program); current status should be verified |
STEMI reperfusion injury | Elamipretide | Stealth BioTherapeutics (US) | Mitochondria-targeted peptide | Failed in STEMI (EMBRACE STEMI); pivoted to other indications |
STEMI reperfusion injury | Cyclosporine (mPTP inhibition) | Generic | Mitochondrial permeability transition pore | Failed in Phase III (CIRCUS, CYCLE) |
STEMI reperfusion injury | Remote ischaemic conditioning (device/procedure) | Various | Conditioning | Neutral in CONDI-2/ERIC-PPCI |
Anthracycline cardiotoxicity | Dexrazoxane (Zinecard; Totect/Savene) | Pfizer; Clinigen (and generics) | Iron chelation / topoisomerase IIβ | Approved; the only approved cardioprotectant; use restricted by label and tumour-protection concerns |
Anthracycline cardiotoxicity | Repurposed cardiology drugs (ACE inhibitors, beta-blockers, statins) | Generic | Neurohormonal | Off-label; mixed evidence |
Ischaemic stroke neuroprotection | Nerinetide | NoNO Inc. (private, Canada) | PSD-95 inhibitor | Phase III (ESCAPE-NA1, FRONTIER); mixed results |
Ischaemic stroke neuroprotection | ARG-007 | Argenica Therapeutics (ASX: AGN) | Cationic arginine-rich peptide | Phase II; direct ASX peer |
Ischaemic stroke / TBI | Glibenclamide IV (BIIB093) | Biogen | SUR1-TRPM4 inhibitor | Large hemispheric infarction program discontinued |
TRPC6 inhibition (other indications) | BI 764198 | Boehringer Ingelheim | TRPC6 inhibitor | Phase II (FSGS); validates TRPC6 as a druggable target |
TRPC5 inhibition | GFB-887 | Goldfinch Bio (wound down 2023) | TRPC5 inhibitor | Discontinued |
Cardio-renal / heart failure (ASX peer) | VB0004 / VB0395 | Vectus Biosystems (ASX: VBS) | Anti-fibrotic | Early clinical |
Peer Comparison FY2026
| Metric | Nyrada (NYR) | Noxopharm (NOX) |
|---|---|---|
Lead stage | Phase IIa (STEMI) | Preclinical / early clinical |
Latest annual net loss | A$6.56m (FY2026) | — |
Cash (latest) | A$8.38m (Jun-2026), before the A$12m Sept-2026 raise | — |
R&D intensity | Majority of opex (H1 FY2025: about 79% of opex) | — |
Market cap | About A$130–181m (sources conflict, Aug–Oct 2026) | About A$20m (TipRanks, 2025) |
Recent Developments
--



